Company Update - Cumberland Pharmaceuticals Inc. will release its third quarter 2024 financial results and provide a company update on November 7, 2024, after market close [1] - A conference call is scheduled for November 7 at 4:30 p.m. Eastern Time to discuss the results, with registration available online [1][2] Product Portfolio - Cumberland Pharmaceuticals focuses on developing, acquiring, and commercializing unique products for hospital acute care, gastroenterology, and oncology markets [3] - The company's FDA-approved products include Acetadote®, Caldolor®, Kristalose®, Sancuso®, Vaprisol®, and Vibativ®, which address various medical conditions such as acetaminophen poisoning, pain and fever, constipation, chemotherapy-induced nausea, hyponatremia, and serious bacterial infections [3] Clinical Programs - The company is conducting Phase II clinical programs for its ifetroban product candidate, targeting conditions such as Systemic Sclerosis, cardiomyopathy associated with Duchenne Muscular Dystrophy, and Idiopathic Pulmonary Fibrosis [4]
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS